Neumentum Enters into Global Licensing Agreement for a Novel Class of Investigational Pain Treatments

JNJ-10450232 is neither an opioid nor an NSAID. The target indication for JNJ-10450232 is for moderate to moderately severe acute pain. Phase 2A clinical studies have been completed for this compound. If successfully developed through additional clinical trials, and if ultimately approved by FDA, this portfolio of compounds may provide new options for pain relief.

“By strategically expanding our pipeline, Neumentum will be well positioned to address patients’ and providers’ needs for acute pain relief in both hospital and community settings, with both IV and oral non-opioid products”, said Scott Shively, chief executive officer of Neumentum. “There is a real lack of innovation in the pain management space, despite a growing need for new options that are safe and effective.”

“We are committed to exploring the potential of these compounds, which we believe are unique,” said Joseph Pergolizzi, M.D., executive chairman of Neumentum.

This deal complements Neumentum’s existing portfolio, particularly the company’s lead product candidate, NTM-001. NTM-001 is a novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous infusion that is in development for the short-term management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting, for up to 24 hours.

About Neumentum
Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company, with product candidates that have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids. The company is led by a world-class executive team of biotech and pharmaceutical industry leaders who have extensive pain and neurology experience, from drug development through commercialization.

For more information, visit Neumentum.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005228/en/